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Abstract
MicroRNAs are short non-coding single stranded RNAs that regulate gene expression. While much is known about the
effects of individual microRNAs, there is now growing evidence that they can work in co-operative networks. MicroRNAs are
known to be dysregulated in many diseases and affect pathways involved in the pathology. We investigated dysregulation
of microRNA networks using asthma as the disease model. Asthma is a chronic inflammatory disease of the airways
characterized by bronchial hyperresponsiveness and airway remodelling. The airway epithelium is a major contributor to
asthma pathology and has been shown to produce an excess of inflammatory and pro-remodelling cytokines such as TGF-b,
IL-6 and IL-8 as well as deficient amounts of anti-viral interferons. After performing microRNA arrays, we found that
microRNAs -18a, -27a, -128 and -155 are down-regulated in asthmatic bronchial epithelial cells, compared to cells from
healthy donors. Interestingly, these microRNAs are predicted in silico to target several components of the TGF-b, IL-6, IL-8
and interferons pathways. Manipulation of the levels of individual microRNAs in bronchial epithelial cells did not have an
effect on any of these pathways. Importantly, knock-down of the network of microRNAs miR-18a, -27a, -128 and -155 led to
a significant increase of IL-8 and IL-6 expression. Interestingly, despite strong in silico predictions, down-regulation of the
pool of microRNAs did not have an effect on the TGF-b and Interferon pathways. In conclusion, using both bioinformatics
and experimental tools we found a highly relevant potential role for microRNA dysregulation in the control of IL-6 and IL-8
expression in asthma. Our results suggest that microRNAs may have different roles depending on the presence of other
microRNAs. Thus, interpretation of in silico analysis of microRNA function should be confirmed experimentally in the
relevant cellular context taking into account interactions with other microRNAs when studying disease.
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Introduction
MicroRNAs (miRNAs) are small (20–26 nucleotides) non-
coding RNAs that regulate gene expression post-transcriptionally,
by binding to the 39 UnTranslated Region (39UTR) of their target
mRNAs. MicroRNAs exert their effects via degradation or
translation inhibition of their target mRNAs [1]. The effects of
microRNAs are cell- and dose- dependent for both the miRNA
and the target mRNA [2–4]; in addition, cooperation between
different miRNAs has been shown to target gene networks [5] and
influence disease [6,7]. Thus, the study of miRNAs in cooperating
networks is an emerging subject on the field of microRNAs [7].
However, excluding in silico analysis, few studies have explored
the functional role of two or more microRNAs comparing
individual versus groups of microRNAs [8].
MicroRNAs are subtle master controllers of gene expression
and therefore excellent candidates for study in chronic multifac-
torial diseases such as asthma [9]. Asthma is an inflammatory
disease of the respiratory airways and affects ,300 million people
worldwide [10]. The main features of asthma include bronchial
airflow reversible obstruction with airway remodelling, impaired
innate immunity to viral infections and dysregulated adaptive
immune responses [11]. In asthma, inflammation and remodelling
are intimately intertwined and the bronchial epithelium, initially
thought of as a passive component, has progressively been gaining
more attention [12]. Both at baseline and after stimulation,
bronchial epithelial cells (BECs) from asthmatics have been shown
to produce higher levels of cytokines such as TGF-b, IL-6 and IL-8
[13–16] that are also typically enriched in the lung of asthmatic
patients [17,18]. Therefore, the airway epithelium in asthma does
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not just suffer from the chronic inflammation, but actively
influences it and contributes to the disease through the secretion
of pro-inflammatory factors.
Using murine models, microRNAs such as miR-21, miR-126,
miR-145 or miR-106a have been associated with allergic
responses, potentially reflecting some features of human asthma
[19–22]. The extensively studied miR-155 seems well placed to
have an impact in asthma, encoded in a genomic region that maps
to pollen sensitivity and asthma [23,24]. Additionally, miR-155
deficient mice exhibit not only an impaired immune response but
also dramatic airway remodelling similar to that present in
asthmatic patients [25] Furthermore, we have shown in macro-
phages that miR-155 inhibits the TGF-b and IL-13 pathways
[26,27] which are important cytokines in airway remodelling and
inflammation [18,28].
However important miR-155 may be, it is but a single
microRNA and we hypothesised that multiple microRNAs may
be dysregulated in asthmatic epithelial cells and act as a master
switch to some of the features that define this disease. We intended
to test our hypothesis by using bioinformatics predictions together
with experimental tools to validate the in silico data. We used
asthmatic epithelial miRNA profiling as a model to explore
potential co-operation of networks of microRNAs as opposed to
single microRNAs in disease. Our data show that a network of
microRNAs (miR-18a, miR-27a, miR-128 and miR-155) are
down-regulated and may be involved in the activation of IL-6 and
IL-8 gene transcription in the asthmatic bronchial epithelium.
Importantly, our results strongly indicate that bioinformatics
analysis should be validated by wet lab experiments. Additionally,
our results suggest that microRNAs might have to be studied as co-
operating networks, rather than in isolation, in order to accurately
describe their biological role in a specific cellular context.
Methods
Ethics statement
Ethical approval was given by the Southampton and South
Hampshire Research Ethics Committee (ethics numbers 05/
Q1702/165 and 08/H0502/6). All subjects gave written informed
consent following these guidelines.
Human subjects
All subjects used in this study were non-smokers and were either
healthy volunteer subjects or had asthma with a range of severity.
Patient demographics are shown in Table S1. Asthma was defined
as a physician’s diagnosis of asthma with bronchial hyperrespon-
siveness or evidence of reversibility to salbutamol.
Cell culture
Bronchial Epithelial Cells (BECs) were obtained by bronchial
brushings upon fiber-optic bronchoscopy according to standard
guidelines [29]. Bronchial brushings contained .95% epithelial
cells and there was no significant difference in the proportion
between healthy and asthmatic donors. BECs were cultured in
collagen-coated T25 flasks in BEGM complete medium (Lonza)
and were passaged when 80% confluent. Arrays and validations
were performed using passage 1 cells.
BEAS2B cells [30] were maintained in RPMI 10% FBS and
passaged when 80% confluent.
MicroRNA microarrays
MicroRNA profiling of BECs was done using TaqMan Low
Density Array Human Panel A (376 microRNAs in total and 3
controls, Applied Biosystems). We were able to detect the
expression of 180 miRNAs (47.5%) in all the samples. MicroRNAs
undetermined in more than two samples of the same type (healthy
or asthmatic) were discarded. Controls used were RNU44,
RNU48 and the small RNA U6. Relative expression was
calculated using the Delta Delta Ct method [31]. We used
RNU44 as reference gene since it showed the most consistent Ct
(cycle threshold) values amongst all the donors (24.837660.1694
and 24.89560.2113 for healthy and asthmatic, respectively). We
used the average Delta Ct of the healthy controls as calibrator.
Heatmap in Figure 1 was constructed using MeV [32]. The data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession number GSE61563.
Transfections
BEAS2B were transfected with Interferin (Polyplus) following
manufacturer’s instructions. Antisense oligonucleotides against
hsa-miR-18a, hsa-miR-27a, hsa-miR-128 and hsa-miR-155 were
purchased from Ambion (Life Technologies). 25 nM of each anti-
microRNA individually or in combination (100 nM total) were
transfected using the appropriate amount of Anti-miR-Negative
Control #1 as transfection control. Cells were harvested 24 h
post-transfection for RT-qPCR and ELISA. In the case of TGF-b
stimulation, cells were starved in 2% FBS following transfection.
24 h post-transfection cells were treated with 1 ng/mL TGF-b
and harvested 24 h after stimulation for RT-qPCR analysis.
Reverse transcription and real time PCR (RT-qPCR)
RNA extraction was performed using Tri Reagent (Ambion)
following manufacturer’s instructions. RNA was retro-transcribed
into cDNA using High-Capacity cDNA Reverse Transcription Kit
(Life Technologies) and qPCR was performed using TaqMan
Gene Expression Assays (Life Technologies). For microRNA
validations, TaqMan MicroRNA Assays were used following
manufacturer’s instructions.
Luciferase experiments
pCDNA3.1_27a and pCDNA3.1_128. The genomic regions
encompassing miR-27a and miR-128 were amplified (respectively)
and separately cloned into pCDNA3.1. (-) (Invitrogen). MiR-27a
was cloned between XbaI/BamHI sites and miR-128 between
XhoI/HindIII sites. Primers employed were: miR-27a_HindIII-
XbaI_FOR: AAGCTT TCTAGA AGA GAG GCC CCG AAG
CCT GTG CC, miR-27a_BamHI_REV: GGATCC AGG GGA
CAG GCG GCA AGG CC, miR-128_XhoI_FOR: CTCGAG
CCT AGC TGT TTT CTG TGT AGC and miR-128_Hin-
dIII_REV: AAGCTT CTA TTT CTG AGT ATG ATG CAT
G. pRLTK_WT_39UTR_SMAD2 was generated previously by
cloning the 39UTR of human SMAD2 between XbaI and NotI
sites of the pRLTK vector (Promega) [27]. pRLTK_MUT27a/
128_39UTR_SMAD2 vector containing a mutated version of the
putative binding site for miR-27a and miR-128 between positions
8336–83430 was generated by site-directed mutagenesis on
pRLTK_WT_39UTR_SMAD2 using QuikChange Site-directed
Mutagenesis Kit (Stratagene), following the manufacturer’s
instructions. Mutagenesis primers were: 39UTR_MUT27a/
128_SMAD2_FOR CCT TAG TGG CTG CAT CCT TGG
TGC TCG AGG ATG GAG ATA TTA AAT GTG and
39UTR_MUT27a/128_SMAD2_REV CAC ATT TAA TAT
CTC CAT CCT CGA GCA CCA AGG ATG CAG CCA CTA
AGG.
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Bioinformatics analysis
Pathway analysis for microRNAs was performed using DIANA
microPath [33]. MicroRNA target predictions were performed
using TargetScan and miRanda [34,35]. miRecords [36] was also
used to determine target-microRNA interaction in at least 4 of the
11 databases listed (miRanda, TargetScan, RNA hybrid, Tar-
getScanCons). Further pathway analysis was performed based on
bibliography and using the KEGG database.
Statistical analysis
Statistical analysis was performed using GraphPad 6.0 software.
For the array validation experiments a two-tailed Mann Whitney
test was employed. In anti-microRNA transfections paired t-tests
comparing to Anti-miRNA Negative controls for each experiment
(n = 4 for individual transfections and n= 6 for simultaneous
transfections) were done. ELISA experiments were analysed using
a two-tailed non-parametric test (n = 4).
Results
A microRNA network is down-regulated in asthmatic
bronchial epithelial cells
To test whether microRNAs were deregulated in the asthmatic
bronchial epithelium, we performed Taqman Low Density Arrays
using RNA from primary bronchial epithelial cells (BECs) isolated
by bronchial brushing from healthy (n = 5) and asthmatic subjects
(n = 5) (demographics shown in Table S1). Figure 1A is a
representative heatmap of our results (complete dataset in Table
S2) which showed 33 up-regulated and 91 down-regulated
microRNAs (0.70$fold [asthmatic/healthy]$1.3), respectively.
We validated our array data by performing specific RT-qPCR
assays from BECs isolated from additional donors (13 healthy and
15 asthmatics). Figure 1B shows that we confirmed that micro-
RNAs miR-18a, miR-19b, miR-27a, miR-106, miR-128 and miR-
155 were down-regulated in asthmatic BECs compared to healthy
counterparts while other microRNAs such as miR-34a, miR-93b,
miR-140-5p, miR-152 and miR-374a) showed no differential
expression (Figure S1.).
Pathway analysis shows that dysregulation of miR-18a,
miR-27a, miR-128 and miR-155 may affect TGF-b, IL-6,
IL-8 and IFN pathways in the asthmatic bronchial
epithelium
To identify cellular functions affected by the dysregulation in
microRNA expression we performed in silico analysis. First, we
used mirPath (DIANA-microT_v4.0, [37]). This program analyses
the effect of individual microRNAs, the summative effect of a
group of microRNAs or their intersection in genes targeted as well
as pathways affected. We observed that miR-18a, miR-27a, miR-
128 and miR-155 converged onto the TGF-b, MAPK, Jak-STAT,
mTOR and cytokine-to-cytokine receptor signalling pathways
involved in inflammation and remodelling. We decided to focus on
these microRNAs and performed intersections of the candidate
target genes predicted by DIANA. Venn diagrams of the
overlapping genes for each pathway are shown in Figure S2.
MiR-27a and miR-128 converged on the highest number of
predicted target genes while the genes SMAD2, CDC42,
RPS6KB1, RAP1B and SOS1 were predicted to be targeted by
at least 3 of our candidate microRNAs (dataset in Table S3). These
data suggested a function of this microRNA network (miR-18a,
miR-27a, miR-128 and miR-155) in the inflammatory profile of
asthmatic bronchial epithelial cells.
We then narrowed our search taking into account the
expression of targets in epithelium and their relevance to asthma
and found out that the network of microRNAs showed predicted
targets that mediate the TGF-b and IFN-a/IFN-b signalling
pathways as well as mediators of IL-6 and IL-8 expression
(Figure 2 A–D, respectively). Datasets for each pathway are
present in Table S4. Together, our analysis suggested that down-
regulation of miR-18a, miR-27a, miR-128 and miR-155 in the
asthmatic bronchial epithelium may modulate inflammatory
signalling and the TGF-b, IFN and IL-6/IL-8 pathways.
MiR-18a, miR-27a, miR-128 and miR-155 have common
predicted targets
Following our pathway analysis, we used miRecords [36] to
strengthen DIANA’s in silico predictions. miRecords combines the
datasets of several microRNA-target prediction tools. We took into
account predicted targets for these microRNAs in miRanda,
TargetScan, PITA and RNA Hybrid [35,38–40] given that these
tools consider different parameters when predicting microRNA
seed pairing (conservation, stability of target-miRNA pairing and
RNA secondary structure). Figure 3 is a Venn diagram showing
that the intersection of the targets for these four microRNAs
converges onto six genes, (MBNL2, KCNA1, QKI, SMAD2,
PLAG1 and ATP2B1, Table S5), confirming the previous
predictions of SMAD2 as a common target for the all the
microRNAs in the network (Figure 2A and Table S4).
Direct targeting of SMAD2 by miR-27a and miR-128
MiR-18a and miR-155 have been previously shown to affect
TGF-b activation by directly targeting SMAD2 [27,41]. In order
to test whether SMAD2 is also a direct target of miR-27a and
miR-128 we performed renilla-luciferase reporter assays. The
SMAD2 39UTR predicted to be targeted by miR-27a and miR-
128 was fused to a reporter renilla-luciferase gene and co-
transfected with plasmids expressing miR-27 or miR-128. We used
a Wild Type reporter vector (WT) and a mutated version (MUT)
where the binding site (position 8336–8343) for both miR-27a and
miR-128 was mutated by site directed mutagenesis (Figure 4C).
Co-transfection of the WT vector with plasmids expressing either
miR-27a or miR-128 showed a reduced luminescence, when
compared to the samples co-transfected with control vectors
(Figure 4A and, Figure 4B, respectively). As expected, the
expression of the reporter containing the mutated version of
SMAD2 39UTR was not affected by co-transfection of miR-27a or
miR-128 plasmids.
Taken together, these data confirmed the bioinformatics
prediction that both miR-27a and miR-128 directly target
SMAD2 39UTR between positions 8336–8343.
Effects of miR-18a, miR-27a, miR-128 and miR-155
individual modulation on TGF-b signalling in bronchial
epithelial cells
Bioinformatics analysis and direct targeting assays suggested
that mir-18a, miR-27a, miR-128 and miR-155 may regulate
Figure 1. A network of microRNAs is dysregulated in asthmatic BECs. A: Heatmap showing fold expression of the microRNA array (n = 5 for
healthy and asthmatic). Blue is down-regulated and yellow is up-regulated. B: Array validation. Expression of selected microRNAs was measured by
TaqMan microRNA assays (n = 13 for healthy and n= 15 for asthmatics). ns = non-significant; * = p,0.05; ** = p,0.01, non-parametric unpaired t-test.
doi:10.1371/journal.pone.0111659.g001
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TGF-b effects in the bronchial epithelium through SMAD2 and
other mediators (Figure 2, Figure 3, Figure 4 and [27,41]). Due to
the importance of the TGF-b pathway in remodelling in asthma
[42,43] we decided to determine the role of these microRNAs on
the TGF-b pathway. We blocked their function by transfecting
inhibitory oligonucleotides (anti-miRs) against each individual
miRNA into human bronchial epithelial cells (BEAS2B) (Figure
S3) and measured the effect on TGF-b signalling and mediators.
Following the in silico predictions and experimental evidence
regarding SMAD2 (Figure 2, Figure 3 and Figure 4), we expected
that blocking individual microRNAs would enhance the TGF-b
pathway by increasing the levels of SMAD2 but also of other
targets such as SMAD3 and SMAD4 and the TGF-b Receptors
(TGFBR 1 and TGFBR2) (see Figure 2A).
We first determined the mRNA expression of the TGF-b
primary transduction pathway genes SMAD2, SMAD3, SMAD4
and SMAD7, as well as the TGFBR1 and TGFBR2 in BEAS2B
cells transfected with anti-microRNA oligonucleotides individually
targeting mir-18a, miR-27a, miR-128 and miR-155. MicroRNA
inhibition seemed to have no effect on the mRNA expression of
the TGF-b mediators assays (Figure 5A). We also determined
protein levels of the direct target of all miRNAs SMAD2 by
Western Blot. Although a modest trend was observed, no
significant SMAD2 protein up-regulation when comparing specific
anti-miRs to scrambled control was observed, with the exception
of anti-miR-128 transfection (Figure S4).
In order to evaluate whether this minor effect (or any other
effect on mediators that we had not considered) had any
consequences on TGF-b signalling, we performed experiments
where cells were transfected with anti-miR oligonucleotides and
treated or not with 1 ng/mL TGF-b after 24 hours, harvesting
after an additional 24 hours for RT-qPCR analysis. We quantified
the mRNA expression of two TGF-b dependent genes: COL1A2
(collagen type 1 alpha 2) and SERPINE1 (Plasminogen Activator
Inhibitor Type 1) [44,45]. As expected, TGF-b treatment led to up
regulation of SERPINE1 and COL1A2 mRNA expression.
However inhibition of miRNAs individually led to an unexpected
mild decrease in SERPINE1 mRNA levels upon TFG-b
stimulation compared to stimulated control anti-miR transfected
cells (Figure 5B left panel). COL1A2 expression was significantly
down regulated by anti-miR-18a and -27a (Figure 5B right panel).
Taken together, our results suggested that despite strong
bioinformatics predictions and preliminary luciferase assays in
HeLa cells, individual microRNAs down-regulated in asthmatic
epithelium do not increase SMAD2 levels or TGF-b activity in
human bronchial epithelial cells.
Effects of individual modulation of miR-18a, miR-27a,
miR-128 and miR-155 on the inflammatory profile of
bronchial epithelial cells
Our in silico data also suggested a role for miR-18a, miR-27a,
miR-128 and miR-155 (Figure 2 and Figure S2) in the inflam-
matory profile of the airway epithelium of asthmatics. Asthmatic
epithelium shows an exacerbated inflammatory status with over-
expression of cytokines such as IL-6 and IL-8 that play also an
important role in remodelling [17,46,47]. Interestingly, several
cytoplasmic and nuclear factors involved in the regulation of IL-6
and IL-8 were predicted targets of the network of microRNAs
(Figure 2C and Figure 2D). Also, several inflammatory mediators,
of potential relevance to asthma, such as SOCS1, IL1B, IL13RA1
and CCL26 [48–51] could be potentially affected, directly or
indirectly by one or more microRNAs of this list. One interesting
possibility was that microRNA down-regulation would result in an
increase of these cytokines and result in augmented inflammation.
We thus analysed the effects of individual inhibition of miR-18a,
miR-27a, miR-128 and miR-155 on the expression of inflamma-
tory mediators by RT-qPCR expecting to see an up-regulation of
inflammatory cytokines and chemokines such as IL1B, CCL26,
IL-6 and IL-8 or down regulation in antiviral IFNs. Figure 6
shows that only inhibition of miR-27a led to a modest decrease of
IL1b mRNA expression. MicroRNA modulation showed no effect
on any of the other candidate genes tested.
We therefore concluded that modulation of the individual
microRNAs miR-18a, miR-27a, miR-128 and miR-155 does not
seem to significantly alter the expression of inflammatory
mediators in human bronchial epithelial cells.
Effects of simultaneous down-regulation of microRNAs
on the TGF-b pathway in bronchial epithelial cells
Our results so far showed that modulation of individual
candidate microRNA (Figure 1B) levels did not have an effect
on the TGF-b pathway or on the expression of inflammatory
mediators in bronchial epithelial cells (Figure 5 and Figure 6) in
opposition to our preliminary analysis (Figure 2, Figure 3 and
Figure 4). We wondered whether transfection of an individual
microRNA may have a knock-on effect on the rest of microRNAs
studied explaining this contradiction. We assessed the effects of
inhibition of miR-18a, miR-27a, miR-128 and miR-155 on the
expression of the other miRNAs by qPCR, showing that individual
transfection increased the levels of the rest of microRNAs (Figure
S5). These results suggest that, in order to exert an effect on the
pathways studied, we might need to knock-down all the
microRNAs studied simultaneously. Taking these results into
account and published data showing that microRNAs are able to
work cooperatively [7], we hypothesised that the effects of
microRNA dysregulation may be different when considered
simultaneously, as opposed to individually.
To test this hypothesis we transfected BEAS2B with a pool of
anti-miRs against miR-18a, miR-27a, miR-128 and miR-155
Figure 3. Mir-18a, miR-27a, miR-128 and miR-155 share
predicted targets. Venn diagram showing the interaction between
genes predicted to be targeted by the candidate microRNAs.
doi:10.1371/journal.pone.0111659.g003
Figure 2. MiR-18a, miR-27a, miR-128 and miR-155 are predicted to target inflammatory pathways. A, B, C, and D: Interferon (IFN) alpha
and beta signalling pathway, TGF-b signalling pathway, IL-6 and IL-8 secretion pathways, respectively, with the different microRNAs targeting
effectors in each pathway.
doi:10.1371/journal.pone.0111659.g002
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(hence forth Anti-MiX), in order to diminish their expression
simultaneously (Figure S6). We expected that this simultaneous
knock-down could confirm the in silico prediction of an
enhancement of the TGF-b pathway (Figure 2A).
We first analysed the effect of microRNA down-regulation on the
TGF-b signalling cascade components. Figure 7A shows that the
simultaneous down-regulation of the pool of microRNAs in
BEAS2B cells had no effect on the mRNA levels of the TGF-b
signal transducers analysed. We also evaluated the levels of SMAD2
protein by western blot in BEAS2B cells transfected with Anti-MiX
as compared to control and observed no differences (Figure S7).
To investigate whether TGF-b signalling could be affected through
other untested mediators, we determined the levels of TGF-b-
dependent genes after TGF-b stimulation in BEAS2B cells transfected
with Anti-MiX. Figure 7B shows that Anti-MiX transfection had no
effect on the TGF-b dependent activation of SERPINE1 and
COL1A2 mRNA expression. Thus, our data suggested that the pool
of microRNAs does not modulate the activity of TGF-b or the levels of
TGF-b pathway transducers in the bronchial epithelium.
Figure 4. MiR-27a and miR-128 directly target the 39UTR of SMAD2. A Renilla luciferase construct harbouring an SMAD2 39-UTR fragment
containing the predicted binding sites for miR-27a and miR-128 (wild type, WT) or its mutated version for both miRNAs binding (MUT) was co-
transfected with either an empty expression vector, a miR-27a over-expressing vector (WT+27a and MUT+27a, respectively) or an miR-128 over-
expressing vector (WT+128 and MUT+miR-128, respectively. One of three independent experiments is shown. Where no significance is shown=non-
significant, ***p#0.001. Error bars indicate Standard Error. B Schematic representing the binding region (and mutation site) of miR-27 and miR-128 in
SMAD2 39UTR.
doi:10.1371/journal.pone.0111659.g004
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Figure 5. Individual microRNA modulatory effects on the TGF-b pathway. BEAS2B cells were transfected with anti-miRNA oligonucleotides
against miR-18a, miR-27a, miR-128 and miR-155 or Anti-miRNA Control. A: Cells were harvested 24 h post-transfection. TGF-b effectors were analysed
by RT-qPCR. B: 24 h post-transfection cells were stimulated with 1 ng/mL TGF-b and harvested 24 h later. Gene expression was analysed by RT-qPCR.
No symbol: non-significant. n = 4 * =p,0.05; ** = p,0.01; *** = p,0.001, ratio paired t-test.
doi:10.1371/journal.pone.0111659.g005
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Figure 6. Individual microRNAmodulatory effects on inflammatory genes. BEAS2B cells were transfected with anti-miRNA oligonucleotides
against miR-18a, miR-27a, miR-128 and miR-155 or Anti-miRNA Control. Cells were harvested 24 h post-transfection. Inflammatory genes were
analysed by RT-qPCR. No symbol: non-significant. n = 4 * =p,0.05; ** = p,0.01, ratio paired t-test.
doi:10.1371/journal.pone.0111659.g006
MicroRNAs Regulate IL-6 in Bronchio Epithelium
PLOS ONE | www.plosone.org 9 October 2014 | Volume 9 | Issue 10 | e111659
Effects of miR-18a, miR-27a, miR-128 and miR-155
simultaneous down-regulation on the inflammatory
profile of bronchial epithelial cells
After our initial set of results, we wondered whether this
network of microRNAs had a different effect on inflammatory
mediators when co-operating compared to that exerted by the
microRNAs individually (Figure 6). We therefore analysed the
effects of the simultaneous down-regulation of our candidate
microRNAs on the inflammatory mediators included in Figure 6.
We found that simultaneous down-regulation of miR-18a, miR-
27a, miR-128 and miR-155 in bronchial epithelial cells signifi-
cantly increased both interleukin IL-6 and IL-8 mRNA levels
(Figure 8). None of the other genes tested (CCL26, IL1B, SOCS1,
IFNA1, IFNA2, IFNB, IL13RA1, IL4) showed significant
differences (Figure 8).
Figure 7. MicroRNA network modulatory effects on the TGF-b pathway. BEAS2B cells were transfected with anti-miRNA oligonucleotides
against miR-18a, miR-27a, miR-128 and miR-155 together (Anti-MiX) or Anti-miRNA Control. A: Cells were harvested 24 h post-transfection. TGF-b
effectors were analysed by RT-qPCR B: 24 h post-transfection cells were stimulated with 1 ng/mL TGF-b and harvested 24 h later. Gene expression
was analysed by RT-qPCR. n = 6. No symbol = non-significant * =p,0.05, ratio paired t-test.
doi:10.1371/journal.pone.0111659.g007
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Figure 8. A microRNA network modulates IL-6 and IL-8 mRNA expression. BEAS2B cells were transfected with anti-miRNA oligonucleotides
against miR-18a, miR-27a, miR-128 and miR-155 together (Anti-MiX) or Anti-miRNA Control. Cells were harvested 24 h post-transfection.
Inflammatory genes were analysed by RT-qPCR. n = 6. No symbol: non-significant. * = p,0.05; ** = p,0.01, ratio paired t-test.
doi:10.1371/journal.pone.0111659.g008
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Our results suggest that miR-18a, miR-27a, miR-128 and miR-
155 work as a co-operative network, and that simultaneous down-
regulation of this network in asthmatic epithelium may lead to an
over expression of IL-6 and IL-8.
MicroRNA inhibition modulates the secretion of IL-6 in
human bronchial epithelial cells
MicroRNAs act post-transcriptionally by degrading mRNA and
also by blocking mRNA translation. Our results so far showed that
the network of microRNAs – and not the individual microRNAs
separately- was regulating the expression of IL-6 and IL-8 at the
mRNA level (Figure 8). To confirm these findings at the protein
level we assayed secretion of IL-6 and IL-8 by ELISA on the
supernatant of BEAS2B cells transfected with inhibitors of the
candidate miRNAs individually or as a network.
Figure 9A (left) shows that inhibition of individual microRNAs
led to a significant decrease of IL-8 secretion in all cases except for
miR-155 inhibition, while the pool of microRNAs seemed to
produce a non-significant increase on IL-8 secretion (p = 0.1544,
Figure 9A right panel). Inhibition of individual microRNAs did
not alter the secretion of IL-6 (Figure 9B left panel). Importantly,
when all microRNAs where inhibited together, we observed a
significant increase in the secretion of IL-6 cytokine (Figure 9B,
right panel).
Taken together our results show that microRNAs, acting as a
network, may show opposite effects to individual microRNAs. In
our study, the functional role of the network may explain the
increased secretion of important inflammatory cytokines in
asthma, such as IL-6 or IL-8, while the individual microRNAs
do not seem to be involved in any of the potentially pathological
pathways tested (remodelling or inflammation).
Discussion
In this study we show a novel and relevant role for a network of
microRNAs as the possible molecular mechanism underlying IL-6-
and IL-8-mediated inflammation in the asthmatic epithelium. We
make an important observation of broader consequences in the
study of microRNAs in disease: microRNAs may have different
and even opposite effects when co-operating in groups rather than
when acting individually.
We found that miR-18a, mir-27a, miR-128 and miR-155 were
down-regulated in BECs from asthmatics compared to healthy
Figure 9. A microRNA network affects IL-6 secretion in bronchial epithelial cells. BEAS2B cells were transfected with anti-miRNA
oligonucleotides against miR-18a, miR-27a, miR-128 and miR-155 separately or together (Anti-MiX) or Anti-miRNA Control. Cells were harvested 24 h
post-transfection. IL-8 (A) and IL-6 (B) secretion was measured by ELISA. n = 4 ns: non-significant. * = p,0.05; ** = p,0.01, ratio paired t-test.
doi:10.1371/journal.pone.0111659.g009
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donors (Figure 1). Using several bioinformatics tools, we predicted
that these microRNAs may play a role in airway inflammation and
remodelling by targeting multiple mRNAs and affecting inflam-
matory mediators important in asthma such as TGF-b, IFNs, IL-6
and IL-8 (Figure 2 and Figure S2) [15,17,18,52].
Regardless of our assays showing direct targeting (Figure 4),
published evidence in other cell types [27,41] and strong in silico
predictions (Figure 2 and Figure 3) neither the individual nor the
simultaneous inhibition of these four microRNAs in human
bronchial epithelial cells increased the downstream signalling of
TGF-b (Figure 5 and Figure 7). Additionally, potential inflamma-
tory targets seemed to be equally unaffected when microRNAs
were knocked-down individually (Figure 6). These data underline
the importance of wet lab experiments in the relevant cellular
model to validate bioinformatics predictions. Interestingly, simul-
taneous down-regulation of the four miRNAs led to an increase in
IL-6 and IL-8 mRNA and IL-6 protein expression in human
bronchial epithelial cells (Figure 8 and Figure 9). Over-expression
of IL-8 has been long associated with asthma and inflammation
[53] and it is thought to cause neutrophil recruitment, which is one
of the hallmarks of virus-induced asthma exacerbations [54]. IL-6
has been inversely correlated with lung function in asthmatics [17]
and in mice exposure to allergen can trigger the production of this
cytokine [55]. Our data suggest that deficiency of microRNAs may
contribute to the exacerbated expression of both IL-6 and IL-8 in
asthma.
Our analysis suggests that the microRNA network may exert its
effect not through a single target but a combination of targets such
as transcription factors NFATs, NFKB, CREB1, CEBPB,
CEBPA, GR, RELA (Figure 2 and Table S4) and signalling
transducers MAPK and mTOR that may contribute to the
regulation of IL-6 and IL-8 expression (Table S3). Thus,
simultaneous down-regulation of the microRNA network but not
the individual microRNAs may cause mild disruptions to different
signalling pathways that, by accumulation, might lead to the over-
expression of IL-6 and IL-8 mRNA (Figure 8).
There are several studies that are in agreement with our data.
For example, Forrest et al identified four microRNAs up-regulated
during monocyte differentiation and showed that their simulta-
neous over-expression triggers specific pro-differentiative changes
not elicited by the over-expression of the individual microRNAs.
Interestingly, two of those miRNAs would also target a microRNA
with anti-differentiative role [56]. Chang et al showed that none of
the individual microRNAs studied were able to suppress CD3-
triggered proliferation of CD4+ T cells, while this was achieved by
microRNAs working in groups [8]. Also, Yao et al showed how
miR-155 affects SOCS1 but not some of the other confirmed
targets SMAD2 and SMAD5 [57]. This co-operative function may
be due to reprogramming of mRNA targeting by microRNAs by
affecting the secondary structure of the 39UTR of their targets
[39,58]. It is also possible that changes in miRNA levels may affect
the expression of one or more microRNAs, or modify the levels –
and thus affect avidity- of their target mRNAs [59,60]. Also,
competition for Argonaute proteins that are essential to the RISC
complex and to microRNA activity [61] may contribute to this
reprogramming of microRNA function [62].
It is important to note that we do not rule out the role of other
microRNAs that may change the function of the microRNA
network. Our data suggests that individual modulation of specific
miRNAs may affect the levels of the other miRNAs (Figure S5),
with consequences that are difficult to predict. Additionally, the
exact levels of microRNAs in the cell may be essential to their role;
we have manipulated microRNA expression but the down-
regulation achieved may not be an exact mimic of the actual
microRNA levels in the diseased cells. Our own data preclude us
from pursuing a reliable molecular mechanism of action for the
increase in IL-6 and IL-8 mRNA expression; miR-128 targets
SMAD2 39UTR directly (Figure 4) and anti-miR-128 increases
SMAD2 protein (Figure S4), however, miR-128 down-regulation
seems to reduce TGF-b signalling rather than increase it
(Figure 5B). Regardless of these limitations, this network of
microRNAs may potentially be used as a therapy to balance the
levels of IL-6 and IL-8 in asthma with a low off-target effect (as
shown in Figure 5, Figure 6, Figure 7, Figure 8 and Figure 9). In
vivo work and then pre-clinical testing would be needed to validate
a potential benefit to asthmatic patients.
In summary, we present an important and novel finding:
microRNAs miR-18a, miR-27a, miR-128 and miR-155 work as a
network and regulate the expression of IL-6 and IL-8 in the
bronchial epithelium. Additionally, our work demonstrates the
need of experimental testing of in silico predictions and the
importance of considering the role of several microRNAs
simultaneously when assessing the effects of miRNAs in disease.
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